Literature DB >> 24294499

Efflux transport of serum amyloid P component at the blood-brain barrier.

Szilvia Veszelka, Judit Laszy, Tamás Pázmány, László Németh, Izabella Obál, László Fábián, Gábor Szabó, Csongor S Abrahám, Mária A Deli, Zoltán Urbányi.   

Abstract

Serum amyloid P component (SAP), a member of the innate immune system, does not penetrate the brain in physiological conditions; however, SAP is a stabilizing component of the amyloid plaques in neurodegenerative diseases. We investigated the cerebrovascular transport of human SAP in animal experiments and in culture blood-brain barrier (BBB) models. After intravenous injection, no SAP could be detected by immunohistochemistry or ELISA in healthy rat brains. Salmonella typhimurium lipopolysaccharide injection increased BBB permeability for SAP and the number of cerebral vessels labeled with fluorescein isothiocyanate (FITC)-SAP in mice. Furthermore, when SAP was injected to the rat hippocampus, a time-dependent decrease in brain concentration was seen demonstrating a rapid SAP efflux transport in vivo. A temperature-dependent bidirectional transport of FITC-SAP was observed in rat brain endothelial monolayers. The permeability coefficient for FITC-SAP was significantly higher in abluminal to luminal (brain to blood) than in the opposite direction. The luminal release of FITC-SAP from loaded endothelial cells was also significantly higher than the abluminal one. Our data indicate the presence of BBB efflux transport mechanisms protecting the brain from SAP penetration. Damaged BBB integrity due to pathological insults may increase brain SAP concentration contributing to development of neurodegenerative diseases.

Entities:  

Keywords:  blood–brain barrier; brain efflux transport; brain endothelial cells; lipopolysaccharide; neurodegenerative diseases; neuroimmunology; permeability; serum amyloid P component

Year:  2013        PMID: 24294499      PMCID: PMC3838545          DOI: 10.1556/EuJMI.3.2013.4.8

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  59 in total

1.  New features of invasive candidiasis in humans: amyloid formation by fungi and deposition of serum amyloid P component by the host.

Authors:  Kevin B Gilchrist; Melissa C Garcia; Richard Sobonya; Peter N Lipke; Stephen A Klotz
Journal:  J Infect Dis       Date:  2012-07-16       Impact factor: 5.226

2.  Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis.

Authors:  F Coria; E Castaño; F Prelli; M Larrondo-Lillo; S van Duinen; M L Shelanski; B Frangione
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

3.  Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease.

Authors:  Agueda Rostagno; Tammaryn Lashley; Douglas Ng; Jordana Meyerson; Hans Braendgaard; Gordon Plant; Marie Bojsen-Møller; Janice Holton; Blas Frangione; Tamas Revesz; Jorge Ghiso
Journal:  J Neurol Sci       Date:  2007-03-21       Impact factor: 3.181

4.  Evidence for an extended interacting surface between beta-amyloid and serum amyloid P component.

Authors:  István Likó; Marianna Mák; Eva Klement; Eva Hunyadi-Gulyás; Tamás Pázmány; Katalin F Medzihradszky; Zoltán Urbányi
Journal:  Neurosci Lett       Date:  2006-12-04       Impact factor: 3.046

5.  Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q.

Authors:  Robert Veerhuis; Ronald S Boshuizen; Michela Morbin; Giulia Mazzoleni; Jeroen J M Hoozemans; Johannes P M Langedijk; Fabrizio Tagliavini; Jan P M Langeveld; Piet Eikelenboom
Journal:  Neurobiol Dis       Date:  2005 Jun-Jul       Impact factor: 5.996

6.  Accumulation and expression of serum amyloid P component in human atherosclerotic lesions.

Authors:  Zhiqing Song; Lei Cai; Ling Guo; Yoshitane Tsukamoto; Chikao Yutani; Xiang-An Li
Journal:  Atherosclerosis       Date:  2010-02-06       Impact factor: 5.162

Review 7.  Amyloidosis and Alzheimer's disease.

Authors:  Jorge Ghiso; Blas Frangione
Journal:  Adv Drug Deliv Rev       Date:  2002-12-07       Impact factor: 15.470

8.  Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Authors:  M B Pepys; J Herbert; W L Hutchinson; G A Tennent; H J Lachmann; J R Gallimore; L B Lovat; T Bartfai; A Alanine; C Hertel; T Hoffmann; R Jakob-Roetne; R D Norcross; J A Kemp; K Yamamura; M Suzuki; G W Taylor; S Murray; D Thompson; A Purvis; S Kolstoe; S P Wood; P N Hawkins
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

9.  Serum amyloid P component-induced cell death in primary cultures of rat cerebral cortex.

Authors:  Z Urbányi; V Lakics; S L Erdö
Journal:  Eur J Pharmacol       Date:  1994-08-03       Impact factor: 4.432

10.  Localization of amyloid P component in human brain: vascular staining patterns and association with Alzheimer's disease lesions.

Authors:  L S Perlmutter; E Barrón; M Myers; D Saperia; H C Chui
Journal:  J Comp Neurol       Date:  1995-01-30       Impact factor: 3.215

View more
  2 in total

1.  Interacting partners of macrophage-secreted cathepsin B contribute to HIV-induced neuronal apoptosis.

Authors:  Yisel M Cantres-Rosario; Natalia Hernandez; Karla Negron; Juliana Perez-Laspiur; John Leszyk; Scott A Shaffer; Loyda M Meléndez
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

2.  Dementia in the older population is associated with neocortex content of serum amyloid P component.

Authors:  Stephan Ellmerich; Graham W Taylor; Connor D Richardson; Thais Minett; Amand Floriaan Schmidt; Carol Brayne; Fiona E Matthews; Paul G Ince; Stephen B Wharton; Mark B Pepys
Journal:  Brain Commun       Date:  2021-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.